Media and Communications

News

2010 News Releases

Thursday, December 23, 2010
FDA Issues Complete Response Letter for Lower-Volume Glatiramer Acetate sNDA

Jerusalem, Israel, December 23, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for a lower-volume (0.5mL) injection of glatiramer acetate. Copaxone® containing 20mg of glatiramer acetate in 1ml is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS).The complete response letter stated that the FDA could not approve the application as submitted. The FDA noted that the 0.5mL formulation co Read More »

Tuesday, December 21, 2010
Teva and Takeda Settle Generic ACTOS® and ACTOplus met® Litigation

Jerusalem, Israel, December 21, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has entered into an agreement with Takeda Pharmaceutical Company Limited to settle patent litigation related to Teva's generic versions of Takeda's ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl) for the United States. Takeda has granted Teva a license to market an authorized generic version of ACTOS® in the U.S. beginning on August 17, 2012, or earlier under certain circumstances. Furthermore, Takeda has granted Teva a license to market an authoriz Read More »

Sunday, December 12, 2010
Teva Files Citizen Petition Surrounding Purported Generic Version of Copaxone®

Jerusalem, Israel, December 12, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that the company has filed a Citizen Petition (CP) with the U.S. Food and Drug Administration (FDA) requesting that the FDA refuse to approve any abbreviated new drug application (ANDA) for a purported generic version of COPAXONE® (glatiramer acetate injection).Teva's requests in this CP are based on the inability to establish acceptable "sameness" of the active ingredients in glatiramer acetate, the complexity of the mechanism of action of a glatiramoid and the inapplicability o Read More »

Thursday, December 09, 2010
Teva Announces Successful Results of Phase III Study with Oral Laquinimod For Multiple Sclerosis

- Laquinimod study met primary endpoint of reducing annualized relapse rate - Treatment with laquinimod significantly slowed progression of disability - Laquinimod data showed a favorable safety and tolerability profileJerusalem, Israel, December 9, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in Read More »

Monday, December 06, 2010
Teva to Present at the NASDAQ OMX 25th Investor Program

Jerusalem, Israel, December 6, 2010 - Jerusalem, December 6, 2010 Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the NASDAQ OMX 25th Investor Program in London with Eyal Desheh, Chief Financial Officer, presenting on Tuesday, December 7, 2010.What: Teva Presentation at the NASDAQ OMX 25th Investor Program, LondonWho: Eyal Desheh, Chief Financial Officer, Teva Pharmaceutical Industries When: Tuesday, December 7, 2010 at 9:00 AM (local time) / 4:00 AM ETWhere: www.tevapharm.com/financial/ or http://investor.shareholder.com/nasdaq/london_Dec2010/eventdetail.c Read More »

Thursday, December 02, 2010
Teva Comments on Patent Infringement Lawsuit Filed by Momenta and Sandoz

Jerusalem, Israel, December 2, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) commented today on the patent infringement lawsuit filed by Momenta Pharmaceuticals, Inc. and Sandoz Inc. Teva received a copy of the complaint which claims that the manufacture of its generic Lovenox® (enoxaparin sodium) injection, which is still under active review at U.S. Food and Drug Administration, has infringed Momenta's U.S. Patent Nos. 7,575,886 (the "'886 patent") and 7,790,466 (the "'466 patent"), and will infringe those patents once it is officially approved and marketed in Read More »

Wednesday, December 01, 2010
Teva Announces $1 Billion Share Repurchase Program

Jerusalem, Israel, December 1, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that its Board of Directors has authorized the Company to repurchase (including through one or more subsidiaries) up to an aggregate of $1 billion of its ordinary shares/ADRs over the next 12 months.The Company remains committed to executing its long-term strategic plan, including future acquisitions and expansion of its generic and branded R&D programs, and to achieving the revenue and non-GAAP net income targets presented in January 2010 of $31 billion and $6.8 billion by 2015, respec Read More »

Monday, November 15, 2010
Teva Highlights QNAZE™ HFA Phase III Data at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology

-- Results Demonstrate Teva's Investigational Nasal Aerosol is Efficacious and Safe Among Patients with Seasonal Allergic Rhinitis --Jerusalem, Israel, November 15, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced results from a Phase III study of QNAZE™ (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR), that demonstrated significantly greater symptom relief compared with placebo. The results, presented at the 2010 Annual Meeting of the American College of Allergy, Asthma & I Read More »

Tuesday, November 09, 2010
Teva to Present at the Credit Suisse 2010 Healthcare Conference

Jerusalem, November 9, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Credit Suisse 2010 Healthcare Conference with William Marth, President & CEO, Teva Pharmaceuticals - Americas, presenting on Thursday, November 11, 2010.What: Teva Presentation at the Credit Suisse 2010 Healthcare ConferenceWho: William Marth, President & CEO, Teva Pharmaceuticals AmericasWhen: Thursday, November 11, 2010 at 4:00pm ESTWhere: www.tevapharm.com/financial/ or http://cc.talkpoint.com/cred001/111010a_rb/?entity=8_8QY65MIHow: Live over the Internet -- log on Read More »

Thursday, November 04, 2010
Teva Presents Respiratory Growth Strategy

-- Robust Product Pipeline and Innovative Technology Platform will Drive Growth Globally --Jerusalem, Israel, November 4, 2010 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today hosted its Respiratory Opportunity Meeting for the financial community in New York, featuring in-depth presentations on Teva's current and future respiratory growth strategy. Teva's expertise in the respiratory marketplace, combined with the strength of its unique product pipeline, is expected to contribute approximately $2.4 billion to the Company's overall 2015 targets of $31 billion. Teva intends to file ten Read More »

​​​